Topic Hub
4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 4 of 4 clinical reviews.
Analysis of FDA Adverse Event Reporting System (FAERS) safety signals for Dayvigo (lemborexant), including somnolence, sleep paralysis, complex sleep behaviors, and suicidal ideation reports since approval.
Read clinical reviewA detailed review of Dayvigo (lemborexant) regulatory approvals worldwide, including FDA clearance, EMA authorization, and post-market safety surveillance data from SUNRISE clinical trials.
Read clinical reviewA detailed comparison of how the FDA and EMA evaluated and regulated Dayvigo (lemborexant), including approval timelines, label differences, scheduling, and post-market safety requirements.
Read clinical reviewA clinical review of Dayvigo (lemborexant) regulatory history, current FDA label, post-market safety data, and Eisai's pipeline for next-generation orexin receptor antagonists.
Read clinical review